Although it will be negatively affected by the COVID-19 pandemic in the short term, the US market for aesthetic injectables will grow through 2029, driven primarily by high patient demand, including from emerging patient groups such as men and younger individuals. New advancements in treatments and products—including product approvals for expanded indications for existing products—will also contribute to market growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aesthetic injectable in the US across a 10-year period.

The emergence of COVID-19 is affecting the aesthetic injectable market in the short term.

How will COVID-19 affect procedure volumes?

What will be the impact on market dynamics? What strategies can companies use to remain successful in this market?

New patient populations will drive growth in the aesthetic injectables market.

What is attracting new patient demographics to aesthetic injectable procedures?

At what stage of the product life-cycle is the aesthetic injectable market?

New product approvals will further support market growth.

Which market segments have been most dynamic in terms of product approvals?

Which product approvals will have the strongest impact on the market?

Increasing competition is forcing companies to further invest in marketing efforts to gain or maintain shares in the market.

How will marketing initiatives differ between established companies and new market entrants?

How are companies marketing to new patient demographics such as men and millennials?

Table of contents

  • Aesthetic Injectables - Market Insights - United States

Author(s): Samantha Chow